Management of low bone mineral density in premenopausal women.

McMaster University, Department of Medicine, Hamilton ON.
Journal of obstetrics and gynaecology Canada: JOGC = Journal d'obstetrique et gynecologie du Canada: JOGC 05/2005; 27(4):345-9.
Source: PubMed


To review evidence for management of low bone density in premenopausal women and to establish practical guidelines for management of low bone density in this population by family physicians.
A search of MEDLINE for relevant articles published between January 1990 and May 2004 was conducted. Articles retrieved were graded by level of evidence. Recommendations for diagnosis and therapy were based on evidence from randomized controlled trials and expert consensus.
Low bone density in premenopausal women is not associated with the same increased risk of fracture seen in older women. In the absence of fragility fractures and loss of height, it may be a reflection of low peak bone mass and may represent the normal variation in bone mineral density (BMD). Women may have low bone density secondary to an underlying skeletal or systemic disorder. Common causes of low bone density in premenopausal women include ovulatory disturbances and low body weight.
Osteoporosis is diagnosed in the premenopausal female population in the presence of fragility fractures and is not based solely on the results of BMD testing. Secondary causes of bone loss should be excluded, and any underlying condition contributing to low bone density should be corrected. Antiresorptive therapy has been evaluated only in those premenopausal women who are on glucocorticoid therapy and in those with primary hyperparathyroidism. Only in these conditions has antiresorptive therapy been shown to improve BMD.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Bone marrow edema (BME) of the foot and ankle is a common finding. Based on the causative factors, this condition can be classified into four different groups: mechanical, reactive, ischemic and metabolic BME. Mechanical BME: “Bone bruises”, trabecular fractures, micro fractures and stress fractures. Ischemic BME: osteochondritis dissecans, osteonecrosis. Reactive BME: degenerative or inflammatory arthritis, tendonitis, tumorous lesions, postoperative conditions. Metabolic BME: Transient osteoporosis (syn. bone marrow edema syndrome). The understanding of the causative factors is mandatory to develop a strategy for treatment. Mechanical BME caused by overuse or acute trauma are the most frequent findings in sports. Subtle injuries of the trabecular bone are often not visible on MRI, but can become apparent on high resolution CT. Close co-operation with the radiologist is mandatory to make a precise diagnosis. Nonweight bearing in addition to analgesics and physiotherapy are the major principles in the treatment. However, if possible, local overload or a hind foot malalignment should be reduced by insoles. The off-label use of ilomedin or bisphosphonates can be helpful, although there is still a lack of scientific evidence.ZusammenfassungKnochenmarködeme (KME) an Fuß und Sprunggelenk sind ein häufiger Befund. Basierend auf den zugrundeliegenden Pathomechanismen lassen sich Knochenmarködeme in vier Gruppen klassifizieren: Mechanisch induzierte, reaktive, ischämische und metabolische Knochenmarködeme. Die mechanisch induzierten KME umfassen Diagnosen wie das „Bone bruise”, trabekuläre Frakturen und Mikrofrakturen sowie die Stressfrakturen. Ischämisch bedingte KME sind die Osteochondrosis dissecans und die Osteonekrose. Reaktive KME entstehen auf der Basis degenerativer oder entzündlicher Gelenkerkrankungen sowie postoperativ oder bei Weichteilaffektionen. Die transiente Osteoporose (Syn. Knochenmarködem-Syndrom) ist aufgrund histologischer Daten als metabolisches KME einzustufen. Das Verständnis der zugrundeliegenden Pathologie ist der Schlüssel zur Behandlung der Erkrankung. Im Bereich des Sports finden sich überwiegend mechanisch induzierte KME. Dabei sind diskrete trabekuläre Frakturen auf den MRT-Aufnahmen nicht sichtbar, können aber mit Hilfe der hochauflösenden CT dargestellt werden. Die enge Kooperation mit dem Radiologen ist für eine exakte Diagnose von entscheidender Bedeutung. Entlastung in Kombination mit Analgetika und Physiotherapie sind die Grundprinzipien der Behandlung. Wenn möglich sollten Fußfehlstellungen durch Einlagen korrigiert werden. Der „off label” Gebrauch von Ilomedin oder Bisphosphonaten kann hilfreich sein, eine abschließende wissenschaftliche Einstufung dieser Behandlungsverfahren ist aber noch nicht möglich.
    No preview · Article · Jan 2006 · Fuß & Sprunggelenk
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Osteoporosis is the result of bone loss due to an imbalance in bone turnover such that bone resorption exceeds bone formation. Bisphosphonates are potent inhibitors of osteoclast activity that reduce bone turnover and re-establish the balance between bone resorption and formation. In clinical studies, several bisphosphonates prevent bone loss, preserve bone structure, improve bone strength and, in patients with osteoporosis, substantially reduce fracture risk. They are effective in multiple clinical settings including postmenopausal osteoporosis, low bone mass in men and drug-induced bone loss. Intermittent oral dosing and intravenous administration are more convenient than the original daily dosing regimen. These drugs are generally well tolerated and have an excellent safety profile in that serious side effects are uncommon. Potent bisphosphonates are generally the preferred treatment option for most patients with or at risk for osteoporosis.
    Preview · Article · Sep 2006 · Arquivos Brasileiros de Endocrinologia & Metabologia
  • [Show abstract] [Hide abstract]
    ABSTRACT: During the transition years leading to menopause, the possibility of conception persists, although at a lower rate. Contraceptive choices available to perimenopausal women are as varied as those for their younger counterparts, albeit with some limitations related predominantly to coexisting medical conditions rather than the advancing age itself. In this review, different contraceptive choices pertaining to this age group will be discussed, with a focus on evidence-based data.
    No preview · Article · Nov 2006 · Women s Health
Show more

We use cookies to give you the best possible experience on ResearchGate. Read our cookies policy to learn more.